ID: ALA3629438

Max Phase: Preclinical

Molecular Formula: C23H17NO4S2

Molecular Weight: 435.53

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(c1cccc(O)c1)c1ccc(-c2cccc(NS(=O)(=O)c3ccccc3)c2)s1

Standard InChI:  InChI=1S/C23H17NO4S2/c25-19-9-5-7-17(15-19)23(26)22-13-12-21(29-22)16-6-4-8-18(14-16)24-30(27,28)20-10-2-1-3-11-20/h1-15,24-25H

Standard InChI Key:  ZWJIJXZDRXHGET-UHFFFAOYSA-N

Associated Targets(Human)

Estradiol 17-beta-dehydrogenase 1 2224 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Estradiol 17-beta-dehydrogenase 2 1671 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Estradiol 17-beta-dehydrogenase 1 138 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Estradiol 17-beta-dehydrogenase 2 138 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 435.53Molecular Weight (Monoisotopic): 435.0599AlogP: 5.15#Rotatable Bonds: 6
Polar Surface Area: 83.47Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 7.77CX Basic pKa: CX LogP: 5.17CX LogD: 5.03
Aromatic Rings: 4Heavy Atoms: 30QED Weighted: 0.41Np Likeness Score: -1.07

References

1. Abdelsamie AS, Bey E, Gargano EM, van Koppen CJ, Empting M, Frotscher M..  (2015)  Towards the evaluation in an animal disease model: Fluorinated 17β-HSD1 inhibitors showing strong activity towards both the human and the rat enzyme.,  103  [PMID:26322835] [10.1016/j.ejmech.2015.08.030]
2. Abdelsamie AS, Herath S, Biskupek Y, Börger C, Siebenbürger L, Salah M, Scheuer C, Marchais-Oberwinkler S, Frotscher M, Pohlemann T, Menger MD, Hartmann RW, Laschke MW, van Koppen CJ..  (2019)  Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing.,  62  (3): [PMID:30645111] [10.1021/acs.jmedchem.8b01493]

Source